ArticleMolecular oncology2020
Classification of diffuse lower-grade glioma based on immunological profiling.
Article in Molecular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Pooled it
- Identification of abnormal neural language networks by reading "brainprints" in patients with brain tumors.Neuroimage. Reports · 2026Article
- Metabolic profiling defines glioblastoma subtypes with distinct prognoses and therapeutic vulnerabilities.Neuro-oncology · 2026Article
- Leveraging single-cell foundation models for accurate survival outcome prediction.Bioinformatics advances · 2026Article
- Novel metabolic subtypes in IDH-mutant gliomas: implications for prognosis and therapy.BMC cancer · 2025Article
- TGF-β signaling-related signature for predicting prognosis and therapeutic response in lower-grade glioma.Translational cancer research · 2024Article
- Identifying Diffuse Glioma Subtypes Based on Pathway Enrichment Evaluation.Interdisciplinary sciences, computational life sciences · 2024Article
- Glioblastoma microenvironment-from biology to therapy.Genes & development · 2024Review
- Detecting early-warning biomarkers associated with heart-exosome genetic-signature for acute myocardial infarction: A source-tracking study of exosome.Journal of cellular and molecular medicine · 2024Article
- Transcriptomics-based characterization of the immuno-stromal microenvironment in pediatric low-grade glioma.Oncoimmunology · 2024Article
- Radiomics for characterization of the glioma immune microenvironment.NPJ precision oncology · 2023Review
- Review
- KYNU as a Biomarker of Tumor-Associated Macrophages and Correlates with Immunosuppressive Microenvironment and Poor Prognosis in Gastric Cancer.International journal of genomics · 2023Article
- The immune subtypes and landscape of sarcomas.BMC immunology · 2022Article
- New biomarker: the gene HLA-DRA associated with low-grade glioma prognosis.Chinese neurosurgical journal · 2022Article
- Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.Acta neuropathologica communications · 2022Article
- Tumor-Associated Microenvironment of Adult Gliomas: A Review.Frontiers in oncology · 2022Review
- Identification of Potential Immune Checkpoint Inhibitor Targets in Gliomas via Bioinformatic Analyses.BioMed research international · 2022Article
- Identification of Immunological Characteristics and Immune Subtypes Based on Single-Sample Gene Set Enrichment Analysis Algorithm in Lower-Grade Glioma.Frontiers in genetics · 2022Article
- A Novel Multi-Omics Analysis Model for Diagnosis and Survival Prediction of Lower-Grade Glioma Patients.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcriptomic data derived from bulk sequencing have been applied to delineate the tumor microenvironment (TME) and define immune subtypes in various cancers, which may facilitate the design of immunotherapy treatment strategies. We herein gathered published gene expression data from diffuse lower-grade glioma (LGG) patients to identify immune subtypes. Based on the immune gene profiles of 402 LGG patients from The Cancer Genome Atlas, we performed consensus clustering to determine robust clusters of patients, and evaluated their reproducibility in three Chinese Glioma Genome Atlas cohorts. We further integrated immunogenomics methods to characterize the immune environment of each subtype. Our analysis identified and validated three immune subtypes-Im1, Im2, and Im3-characterized by differences in lymphocyte signatures, somatic DNA alterations, and clinical outcomes. Im1 had a higher infiltration of CD8+ T cells, Th17, and mast cells. Im2 was defined by elevated cytolytic activity, exhausted CD8+ T cells, macrophages, higher levels of aneuploidy, and tumor mutation burden, and these patients had worst outcome. Im3 displayed more prominent T helper cell and APC coinhibition signatures, with elevated pDCs and macrophages. Each subtype was associated with distinct somatic alterations. Moreover, we applied graph structure learning-based dimensionality reduction to the immune landscape and revealed significant intracluster heterogeneity with Im2 subtype. Finally, we developed and validated an immune signature with better performance of prognosis prediction. Our results demonstrated the immunological heterogeneity within diffuse LGG and provided valuable stratification for the design of future immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.